Table 1.
Clinical characteristics of the patients.
| Patient 1 | Patient 2 | References | |
|---|---|---|---|
| Age | 4y6m | 7y9m | |
| Gender | Boy | Girl | |
| IgG (g/L) | 20.8 | 19.35 | 6.36–14.04 |
| IgG1 (g/L) | 24.8 | 17.6 | 4.9–11.4 |
| IgG2 (g/L) | 1.87 | 0.47 | 1.5–6.4 |
| IgG3 (g/L) | 0.99 | 1.45 | 0.2–1.1 |
| IgG4 (g/L) | 0.01 | <0.06 | 0.08–1.4 |
| IgM (g/L) | 2.49 | 1.98 | 0.29–1.21 |
| IgA (g/L) | 1.98 | 1.58 | 0.63–1.79 |
| IgE (U/L) | 4.3 | 18 | <100 |
| CD 20 (%) | 4.91 | 23.96 | 14–21 |
| CD3 (%) | 73.46 | 63.57 | 64–72.5 |
| CD4 (%) | 32.06 | 25.58 | 29.5–35.5 |
| CD8 (%) | 37.58 | 31.78 | 24–33.5 |
| CD3-CD16+CD56+ (%) | 12.99 | 15.60 | 11–23 |
| CD4/CD8 | 0.85 | 0.8 | 0.9–1.4 |
| ANA | <1:80 | 1:80 | <1:80 |
| RF (U/ml) | 255 | 26.1 | 0–14 |
| ANCA (PR3) | +++ | +++ | – |
| Blood routine | |||
| WBC counts (109/L) | 3.2 | 10.08 | 4–12 |
| Hgb (g/L) | 112 | 102 | 110–155 |
| PLT (109/L) | 164 | 222 | 100–400 |
| CRP (mg/L) | 10 | 53 | 0–8 |
| ESR (mm/h) | 83 | 0–20 | |
| Urine routine | |||
| RBC counts | 1,637/µl | 491/ul | 0–13.6 |
| WBC counts | 10.3/µl | 5.1/ul | 0–13.2 |
| Proteinuria | + | – | – |
| Proteinuria (mg/24 h) | 106 | 189 | <150 |
| EBVEA-IgM | ++ | – | – |
| EBVCA-IgG | ++ | ++ | – |
| CMV IgM | + | + | – |
| BALF | |||
| Macrophage (%) | 59 | 64 | >85 |
| Lymphocytes (%) | 11.0 | 15 | ≤15 |
| Neutrophil (%) | 30.0 | 21 | <3 |
| Eosinophil (%) | <1 | <1 | <1 |
| RBC | +++ | ++ | – |
ANA, antinuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; BALF, bronchoalveolar lavage fluid; CMV, cytomegalovirus; CRP, C reactive protein; EBVEA, Epstein-Barr virus early antigen; EBVCA, Epstein-Barr virus capsid antigen; ESR, erythrocyte sedimentation rate; RBC, red blood cell; RF, rheumatoid factor; PLT, platelets; WBC, white blood cell.
-, negative; + ∼ +++, positive. +++ refers to the most significant positive result.